Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
This month, we raise awareness about what lung cancer is, how to lower your risk, and how important screening is for those at high risk.
In non-small cell lung cancer, new drugs like brigatinib and crizotinib can dramatically shrink tumors with an ALK alteration.
Lorlatinib shrinks tumors in half of patients previously treated with older ALK inhibitors.
Program designed for patients, caregivers and healthcare providers to learn more about latest trends
The program proved as accurate as experienced pathologists at diagnosing adenocarcinomas and squamous cell carcinomas.
Immunotherapy combination reduced the risk of death by 36 percent compared with chemotherapy alone.
Median overall survival was 15.9 for the combination versus 11.3 months for chemotherapy alone.
Because so few people diagnosed with SCLC survive for even a year despite treatment, an advance in survival rate is quite significant.
Cancer geneticists, epidemiologists and oncologists team up to use mutation rate to predict individual cancer risk.
“The challenge now is to exploit this knowledge for therapeutics,” says researcher Joaquin Espinosa, PhD.
Immunotherapy led to better outcomes for patients with inoperable non-small-cell lung cancer.
Targeted therapy approved first-line treatment of cancer with specific genetic mutations.
Targeted therapy reduced risk of disease progression or death by about 50 percent.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.